
F.D.A. Approves Ozempic to Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both type 2 diabetes and chronic kidney disease.
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than one in seven U.S. adults. The medication can lower the chance that patients with both conditions will undergo worsening kidney disease, kidney failure and death from cardiovascular issues.
'Over the last 20 years, it's been an area where researchers tried hard but delivered very little,' said Dr. Stephen Gough, senior vice president of global medical affairs at Novo Nordisk, the company that makes Ozempic. 'To have something new like this is really exciting, and offers promise to patients,' he said.
The F.D.A. based its decision to expand the approved uses of Ozempic on research showing that people with Type 2 diabetes and chronic kidney disease who took the drug had a 24 percent lower likelihood of experiencing a complication, like requiring dialysis or a transplant, compared to people who took a placebo. They also had slower rates of kidney decline and were less likely to die from cardiovascular problems.
'The more we can delay the decline in kidney function, the better,' said Dr. Melanie Hoenig, a nephrologist at Beth Israel Deaconess Medical Center in Boston. Dr. Hoenig said she already prescribes Ozempic to some of her patients.
Doctors have long expressed frustration with just how few options there are for treatment. Many patients take medications to lower blood pressure, blood sugar and cholesterol, which tend to be elevated in people with chronic kidney disease. Patients also sometimes take drugs to alleviate swelling that occurs when the kidneys can't properly filter fluid, as well as medications to manage iron, calcium and vitamin D levels.
Doctors also routinely encourage lifestyle changes, including diet and exercise modifications, in part because these can help manage Type 2 diabetes. High blood sugar can damage blood vessels in the kidneys, preventing them from filtering waste out of blood. Roughly 40 percent of people with Type 2 diabetes will develop chronic kidney disease, Dr. Gough said.
It isn't clear exactly how Ozempic might benefit the kidneys beyond managing diabetes. Researchers have theorized that Ozempic reduces inflammation throughout the body, including the kidneys. That could help explain why the medication and similar drugs are proving to be so useful for a range of chronic conditions, including cardiovascular issues. The drugs do come with side effects, most commonly gastrointestinal issues like nausea, vomiting and stomach pain.
The approval means that doctors will now be able to prescribe the drug specifically for chronic kidney disease in diabetic patients, and insurance companies will face more pressure to cover Ozempic.
As more people seek out Ozempic, though, Novo Nordisk has struggled to keep up with demand. The F.D.A. lists semaglutide, the compound in Ozempic and the weight loss drug Wegovy, as currently in shortage.
'Many people, unfortunately, cannot get it,' Dr. Hoenig said. 'But if they can and it works for them, and they can tolerate it, it's a wonderful thing to have more tools.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
A new study analyzed patients who used GLP-1 medications in a real-world setting Researchers found that participants lost less weight compared to use in clinical trials They believe discontinuation rates are due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortagesWeight-loss medications like Ozempic and Mounjaro are not as effective in a 'real-world' setting, according to a new study. The study — published June 10 in the Obesity Journal — analyzed nearly 8,000 patients who were classified as having severe obesity. Between 2021 and 2023, they were treated with semaglutide or tirzepatide, injectable GLP-1 medications, in a real-world setting. GLP-1 is short for glucagon-like peptide-1 receptor agonists, which work in the brain to impact satiety. Semaglutide is sold under brand names Ozempic and Wegovy, and tirzepatide is sold under brand names Mounjaro and Zepbound. In a follow-up study, which ended in December 2024, researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! They found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. Additionally, more than 80% of patients were on lower maintenance dosages of their medications. After a year of treatment, the average weight loss was 3.6% for those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who continued treatment lost about 12% of their body weight. During clinical trials for the GLP-1s, patients lost about 15% to 20% of their body weight. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' Dr. Hamlet Gasoyan, Cleveland Clinic researcher and lead author of the study, said in a statement. The study notes that discontinuation rates during real-world use were higher than those in a clinical trial setting due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortages. Read the original article on People
Yahoo
6 hours ago
- Yahoo
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce the risk of head and neck cancer recurrence, progression, or death by 30% compared to current treatments. Keytruda is Merck's best-selling drug, generating more than $7 billion in revenue in the first (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda. The Food and Drug Administration (FDA) has approved Keytruda's use for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express the protein PD-L1. The study's overall principal investigator, Dr. Ravindra Uppaluri, said the approval "represents a potentially significant shift in how we manage this disease." Dr. Uppaluri added Keytruda "has been shown to reduce the risk of recurrence, progression, or death by 30%, compared with standard of care adjuvant chemoradiotherapy or radiotherapy alone." Merck noted that it's estimated that in 2025, there will be approximately 72,680 new cases of head and neck cancer diagnosed, and more than 16,680 deaths from the disease. Keytruda is the company's best-selling drug, with first-quarter revenue of $7.2 billion, making up nearly half of its total sales. Entering Friday trading, shares of Merck were down about 18% year-to-date. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Epoch Times
7 hours ago
- Epoch Times
FDA Approves Moderna's RSV Vaccine for Some Younger Adults, Company Says
Federal regulators approved Moderna's vaccine against Respiratory Syncytial Virus (RSV) for some adults as young as 18, the company said on June 12. The Food and Drug Administration (FDA) expanded approval of the shot to people aged 18 to 59 who face an increased risk from RSV, a virus that typically causes cold-like symptoms, Moderna